Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient

R L Soutar; J Mercer; J E Wraith

doi:10.1007/s10545-006-0329-5

Impact of 144 weeks of laronidase therapy on body functions, endurance and general well-being in a Hurler-Scheie patient

J Inherit Metab Dis. 2006 Aug;29(4):590. doi: 10.1007/s10545-006-0329-5. Epub 2006 Jul 8.

Authors

R L Soutar¹, J Mercer, J E Wraith

Affiliation

¹ Department of Haematology, Western Infirmary, Dumbarton Road, Glasgow, G11 6NT, UK, richard.soutar@northglasgow.scot.nhs.uk.

PMID: 16830264
DOI: 10.1007/s10545-006-0329-5

Abstract

The quality of life of a Hurler-Scheie patient who experienced improvement in several organ functions and regained mobility after 144 weeks of laronidase enzyme replacement therapy is described.

Publication types

Case Reports

MeSH terms

Adolescent
Female
Humans
Iduronidase / administration & dosage
Iduronidase / therapeutic use*
Mucopolysaccharidosis I / drug therapy*
Mucopolysaccharidosis I / physiopathology
Quality of Life*
Recombinant Proteins / administration & dosage
Recombinant Proteins / therapeutic use

Substances

Recombinant Proteins
Iduronidase